Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data

Xiao-lei LAI; Hong-xu LIU; Xin HU; Jing-feng TIAN; Ju-ju SHANG; Xiang LI; Qi ZHOU; Wen-long XING

doi:10.1007/s11655-020-3189-1

Your Location：

Home >

Browse articles >

Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data

Original Article | Updated：2021-09-01

- Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data
- Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data
- Chinese Journal of Integrative Medicine 2021年27卷第5期页码：323-329
- Affiliations：
  
  1.Department of Cardiovascular, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing (100010), China
  2.Department of Rehabilitation, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing (100102), China
- Author bio：
  
  Prof. LIU Hong-xu, E-mail: lhx_@263.net
- Funds：
  
  Beijing Municipal Administration of Hospitals Key Medical Professional Development Program(ZYLX201817)
- DOI：10.1007/s11655-020-3189-1
  中图分类号：
- 纸质出版日期：2021-05-01，
  
  网络出版日期：2020-02-27，
  
  录用日期：2019-10-18
Scan for full text
Xiao-lei LAI, Hong-xu LIU, Xin HU, 等. Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data[J]. Chinese Journal of Integrative Medicine, 2021,27(5):323-329.

Xiao-lei LAI, Hong-xu LIU, Xin HU, et al. Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data[J]. Chinese Journal of Integrative Medicine, 2021,27(5):323-329.
Xiao-lei LAI, Hong-xu LIU, Xin HU, 等. Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data[J]. Chinese Journal of Integrative Medicine, 2021,27(5):323-329. DOI： 10.1007/s11655-020-3189-1.

Xiao-lei LAI, Hong-xu LIU, Xin HU, et al. Acute Myocardial Infarction in Chinese Medicine Hospitals in China from 2006 to 2013: An Analysis of 2311 Patients from Hospital Data[J]. Chinese Journal of Integrative Medicine, 2021,27(5):323-329. DOI： 10.1007/s11655-020-3189-1.

摘要

Abstract

Objective:

To assess the trends in characteristics

treatments

and outcomes of acute myocardial infarction (AMI) patients in tertiary Chinese medicine (CM) hospitals in China between 2006 and 2013.

Methods:

This retrospective study was based on two nationwide epidemiological surveys of AMI in tertiary CM hospitals during 2 years (2006 and 2013). Patients admitted to the hospital for AMI were enrolled. Hospital records were used as the data source. Case data were derived regarding baseline characteristics

treatments

and outcomes of patients to assess changes from 2006 to 2013. Logistic regression was used to analyze the relationship between prognosis

general influencing factors of disease

and various treatment measures.

Results:

Totally 26 tertiary CM hospitals in 2006 and 29 tertiary CM hospitals in 2013 (18 were repetitive) were surveyed. A total of 2

311 patients with AMI were enrolled (1

094 cases in 2006 and 1

217 cases in 2013). From 2006 to 2013

the mean age did not significantly change

but the proportion of patients younger than 65 years increased. The prevalence of risk factors such as hypertension

diabetes

and hyperlipidemia also increased. Significant increases were observed in primary percutaneous coronary intervention [20.48% (2006) vs. 24.90% (2013)] and revascularization [36.11% (2006)

. 52.42% (2013)]. In-hospital mortality decreased from 11.15% in 2006 to 10.60% in 2013. A mortality logistic regression analysis identified reperfusion therapy [odds ratio (OR)

0.222; 95% confidence interval (CI)

0.106-0.464]

Chinese patent medicines (OR

0.394; 95% CI

0.213-0.727)

and CM decoctions (OR

0.196; 95% CI

0.109-0.353) as protective factors.

Conclusion:

Reperfusion and revascularization capabilities of tertiary CM hospitals have improved significantly

but in-hospital mortality has not significantly decreased. Efforts are needed to improve medical awareness of AMI and expand the use of CM to reduce in-hospital mortality in China.

关键词

Keywords

myocardial infarctChinese medicinetraditionalChinahospital mortality

references

WW Chen, RL Gao, LS Liu, ML Zhu, W Wang, YJ Wang, et al.Summary of Chinese cardiovascular disease report 2017. Chin Circ J (Chin) 2018;33:1-8.

G Yang, Y Wang, Y Zeng, GF Gao, X Liang, M Zhou, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987-2015.

J Li, X Li, Q Wang, S Hu, Y Wang, FA Masoudi, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2015;385:402.

HX Liu, SR Wang, D Zhao, Y Lei. Comparative analysis on clinical characteristics and therapeutic status of inpatients with acute myocardial infarction in TCM and Western Medicine Hospitals in Beijing. Int J Emerg Crit Care Med (Chin) 2007;4:1934-1937.

SR Wang, HX Liu, D Zhao, Y Lei, W Wang, JJ Shang. Study on the therapeutic status of 1, 242 hospitalized acute myocardial infarction patients in Beijing. Chin J Epidemiol (Chin) 2006;11:991-995.

L Zheng, HX Liu, JJ Shang. Meta-analysis on the effects of TCM intravenous preparations on the case fatality rate and recanalization rate of acute myocardial infarction. J Emerg Tradit Chin Med (Chin)2007;16:859-860.

F Ying, HX Liu. Fatality rate analysis of TCM treatment on acute myocardial infarction from clinical research literatures of China. Circ Cardiovasc Qual Outcomes (Chin) 2006;13:357-360.

Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of the Chinese Journal of Cardiology. The guidelines for the diagnosis and treatment of acute STEMI. Chin J Cardiol(Chin) 2015;43:380-393.

Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of the Chinese Journal of Cardiology. The guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes. Chin J Cardiol (Chin) 2012;40:353-367.

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-171.

GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1151-1210.

FB Hu, MJ Stampfer, SM Haffner, CG Solomon, WC Willett, JE Manson. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25:1129-1134.

KK Ray, SR Seshasai, S Wijesuriya, R Sivakumaran, S Nethercott, D Preiss, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772.

Y Li, X Zeng, J Liu, Y Liu, S Liu, P Yin, et al. Can China achieve a one-third reduction in premature mortality from non-communicable diseases by 2030. BMC Med 2017;15:132.

HX Liu, W Gao, D Zhao, JJ Shang, JY Sun. Survey on the hospitalization treatment status of acute myocardial infarction patients in 13 hospitals of Western medicine and TCM in Beijing.Chin J Cardiol (Chin) 2010;38:306-310.

N Wang, D Zhao, J Liu, J Liu, CM Yu, W Wang, et al. Impact of heart failure on in-hospital outcomes of acute coronary syndrome patients in China—results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) project. Int J Cardiol 2012;160:15-19.

Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.

SS Gottlieb, RJ McCarter, RA Vogel. Effect of β-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.

EA Amsterdam, NK Wenger, RG Brindis, Casey DEJr, TG Ganiats, Holmes DRJr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-e228.

Smith SCJr, EJ Benjamin, RO Bonow, LT Braun, MA Creager, BA Franklin, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-2473.

JJ Shang, H Shi, Q Zhou, W Gao, HX Liu. A study of prognosis, outcome, and changing tendency of hospitalized AMI patients in Beijing tertiary TCM hospitals from 1999 to 2008. Evid Based Complement Alternat Med 2012;2012:837194.

LS Liu, W Wang, QY Fang, WX Pan, P Huang, FZ Ma, et al. Effects of captopril combined with other drugs on important clinical events in patients with acute myocardial infarction—Sixth special report from the Chinese Cardiac Study-1 (CCS-1). J Hyperten (Chin) 1998;3:7-10.

Y Wang, L Xiao, W Mu, HL Yu, S Zhang, GH Tian, et al. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine. Chin J Integr Med 2017;23:948-955.

YY Jin, H Gao, XY Zhang, H Ai, XL Zhu, J Wang. Shenfu Injection inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock. Chin J Integr Med 2017;23:170-175.

WH Duan, F Lu, LZ Li, CL Wang, JG Liu, QN Yang, et al. Clinical efficacy of traditional Chinese medicine on acute myocardial infarction:a prospective cohort study. Chin J Integr Med 2012;18:807-812.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-Catenin Signaling Pathway